CSL Limited: Is It a Hold for the Rest of 2025?

CSL Limited (ASX: CSL) has long been considered one of Australia’s premier healthcare and biotechnology companies, with global operations spanning plasma therapies, vaccines, and specialty medicines. Investors have traditionally viewed CSL as a defensive stock within the health technology sector, offering resilience and steady earnings even in volatile markets. But with restructuring moves, soft vaccine demand, and share price weakness in 2025, many investors are asking: is CSL still worth holding for the rest of this year?

Industry Backdrop: Health Technology & Biopharma

CSL operates in the health technology and biotechnology space — a sector that remains attractive due to the essential nature of its products. Plasma-derived therapies treat rare and serious disorders, making demand less cyclical than consumer goods or industrial sectors. The vaccine business, though cyclical, positions CSL within global health infrastructure.

The health technology sector itself has seen increased investor attention. From biotech giants like Takeda and Grifols to medical device leaders like ResMed and Sonic Healthcare, the theme is clear: investors are searching for durable, globally scalable healthcare solutions. Opportunities like these are attractive not only for defensive investors but also for younger investors looking to align portfolios with long-term healthcare trends.

Recent Financial Performance & Strategic Initiatives

For FY25, CSL reported revenue growth of around 6% to more than $23 billion, with net profit up by 15%. While headline numbers remain strong, growth has slowed compared to historical averages. Management responded with bold moves:

• Cutting approximately 3,000 jobs and closing 22 underperforming plasma centres.
• Planning a demerger of its vaccine arm, Seqirus, into a separately listed company by FY26.
• Announcing up to US$500 million in annual cost savings over the next three years.
• Increasing dividends 12% up from previous year to $2.46 and committing to a share buyback ($750 million) program.

This restructuring is designed to sharpen CSL’s focus on plasma and specialty medicines while unlocking value from vaccines. Yet, execution risks remain.

Competitors & Case Studies

CSL competes with global plasma and biologics leaders such as Grifols, Baxter, and Takeda. These companies face similar challenges: plasma supply chain bottlenecks, rising regulatory scrutiny, and slower post-pandemic vaccine demand. Historically, when peers such as Takeda have divested non-core units, share prices faced volatility before rebounding as efficiency gains materialised.

Closer to home, investors often compare CSL with Sonic Healthcare or ResMed. While these companies operate in different segments, they highlight how Australian health technology firms can build global scale and deliver strong long-term returns.

Technical Analysis & Valuation

Technically, CSL shares are trading near their lower Bollinger Band at around $199. The Relative Strength Index (RSI) of 31 indicates the stock is in oversold territory, often interpreted as a potential entry point for long-term investors. At 20.95x, the current price-to-earnings ratio marks a five-year low.

For many, the technicals of this stock do position it as a strong holding in diversified portfolios. Long-term holders benefit from defensive healthcare exposure, while shorter-term traders may eye oversold signals for tactical opportunities.

Is CSL a Buy or Hold in 2025?

So, should you buy CSL stock now or simply hold? For existing shareholders, the answer leans towards Hold. The company remains financially solid, with a strong balance sheet, essential products, and a clear plan for the future. For new investors, the current oversold signals could make CSL one of the best stocks to buy and hold for FY26, provided you are willing to wait out near-term volatility.

Opportunities like these are attractive not just for dividend investors but also for younger investors building a long-term portfolio anchored in defensive healthcare growth stocks.

Bottom Line

CSL is not without risks – slower vaccine sales, restructuring costs, and global regulatory pressures are real challenges. But this is also a company that has consistently delivered for decades. With its global footprint, shareholder returns, and essential therapies, CSL continues to justify its place among the top ASX healthcare shares.

For the rest of 2025, CSL looks like a Hold – steady, defensive, and waiting for its next big move. For FY26, however, CSL may well prove why it remains one of the best healthcare stocks to buy and hold in Australia.

Disclaimer:

General Financial Product Advice and Regulatory Framework: Pristine Gaze Pty Ltd (ABN 66 680 815 678, ACN 680 815 678) operates as Corporate Authorised Representative (CAR No. 001312049) of Alpha Securities Pty Ltd (AFSL 330757), which is licensed and regulated by the Australian Securities and Investments Commission under the Corporations Act 2001 (Cth). This report contains general financial product advice only and has been prepared without consideration of your personal objectives, financial situation, specific needs, circumstances, or investment experience. The information is not tailored to individual circumstances and may not be suitable for your particular situation. Before acting on any information contained herein, you should carefully consider its appropriateness having regard to your personal objectives, financial situation, and needs, and consider seeking personal financial advice from a qualified financial adviser who can assess your individual circumstances and provide tailored recommendations.

Investment Risks and Market Warnings: All investments carry significant risk, and different investment strategies may carry varying levels of risk exposure including total loss of invested capital. The value of investments and income derived from them can fluctuate significantly due to market conditions, economic factors, company-specific events, regulatory changes, commodity price volatility, currency fluctuations, interest rate movements, and other factors beyond our control. Securities markets are subject to market risk from general economic conditions and investor sentiment, liquidity risk affecting the ability to buy or sell securities at desired prices, credit risk from issuer default or deterioration, operational risk from inadequate internal processes, sector-specific risks including industry regulatory changes, technology obsolescence, management changes, competitive pressures, supply chain disruptions, and mining-specific risks including resource estimation uncertainty, operational hazards, environmental compliance, permitting delays, commodity price cycles, geopolitical factors affecting mining operations, and exploration risks. Small-cap and speculative mining stocks carry additional risks including limited liquidity, higher volatility, dependence on key personnel, limited operating history, uncertain cash flows, and potential failure to achieve commercial production.

Information Accuracy and Limitations: While we endeavour to ensure information accuracy and reliability, we make no representations or warranties (express or implied) regarding the accuracy, reliability, completeness, timeliness, or suitability of information provided, except where liability cannot be excluded under applicable law. This report may include information from third-party sources including company announcements, regulatory filings, research reports, market data providers, financial news services, and publicly available information, which we do not independently verify and for which we assume no responsibility. Past performance, examples, historical data, or projections are not indicative of future results, and no guarantee of future returns is provided or implied. To the maximum extent permitted by law, Pristine Gaze Pty Ltd and Alpha Securities Pty Ltd, together with their respective directors, officers, employees, representatives, and related entities, exclude all liability for any errors, omissions, inaccuracies, loss or damage (including direct, indirect, consequential, or special damages) arising from reliance on information provided, investment decisions made based on this report, market losses, opportunity costs, and technical issues or system failures.